Could a diabetes drug curb opioid cravings? new study investigates
NCT ID NCT06639464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide, a drug used for diabetes and weight loss, can help people with opioid use disorder reduce cravings and avoid relapse. About 46 adults who are already taking buprenorphine will receive either semaglutide or a placebo for 12 weeks. The goal is to see if semaglutide can make it easier to stay off illicit opioids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tool better measure opioid withdrawal?
- Giving patients a voice in methadone care: a new approach under the microscope
- Can a sleep pill boost success in opioid treatment?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Could a trip to the pediatrician help teens beat opioid addiction?
- A nose spray before treatment: could naloxone speed up opioid recovery for fentanyl users?